<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488982</url>
  </required_header>
  <id_info>
    <org_study_id>055511</org_study_id>
    <secondary_id>NCI-2011-01269</secondary_id>
    <nct_id>NCT00488982</nct_id>
  </id_info>
  <brief_title>Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)</brief_title>
  <official_title>A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-arm, randomized Phase II study of intermittent chemotherapy with and without
      GM-CSF. All patients will receive six 21-day cycles of docetaxel 75 mg/m2 on Day 2 of each
      cycle and 5 mg prednisone twice a day on Days 1-21. Following six cycles of chemotherapy,
      eligible subjects will be randomized to no maintenance therapy or to maintenance GM-CSF
      therapy. The GM-CSF group dose schedule will be 250 mcg/m2 subcutaneous (SQ) daily Days 15-28
      every 28 days. Patients in both groups will continue until disease progression at which time
      GM-CSF will be discontinued and chemotherapy will again be administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The Kaplan-Meier product limit method with 95% confidence intervals will be used to estimate the median time to disease progression during initial course of randomized treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The Kaplan-Meier product limit method will be used to estimate the median overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With PSA Response to Successive Series of Chemotherapy</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>PSA partial response is defined by at least a 50% decline from PSA value from the baseline measurement to 12 weeks of protocol therapy. The decline must be confirmed by a second PSA value obtained 4 or more weeks later For those patients whose PSA have decreased but has not reached response criteria defined above, progressive disease is defined as 25% increase over the nadir PSA value provided that the increase is at least 5ng/mL and is confirmed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Duration of Time on and Off Docetaxel-based Therapy</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Median percentage of time will be calculated to summarize the total duration of chemotherapy and amount of docetaxel/prednisone administered while the patient is on study. The same results will be tabulated for each. For the on-chemotherapy period: will be estimated from the date of starting protocol therapy; if a patient received docetaxel on day 2 of a cycle, he will be considered to have received a full 21 days on therapy. For the off-chemotherapy period: will be calculated from the date of starting the observation or GM-CSF period to the date of resuming chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel + Observation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel + GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75mg/m2 every 21 days</description>
    <arm_group_label>Docetaxel + Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel and GM-CSF</intervention_name>
    <description>Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28</description>
    <arm_group_label>Docetaxel + GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years

          2. Histologically documented adenocarcinoma of the prostate

          3. Progressive metastatic prostate cancer

          4. Castrate levels of testosterone (&lt;50 ng/ml) must be maintained

          5. Prior hormonal therapy or medications :

             Patients who are receiving an anti-androgen, secondary hormonal therapy (i.e.
             ketoconazole, aminoglutethimide, megestrol acetate, diethylstilbestrol), 5-alpha
             reductase inhibitor (i.e. finasteride (Proscar), dutasteride (Avodart)) or herbal
             prostate medication (i.e. saw palmetto, PC-SPES, PC-PLUS) must discontinue the drug by
             the date of initiation of chemotherapy on study

          6. ≥ 4 weeks since major surgery and fully recovered

          7. ≥ 4 weeks since any prior radiation with any toxicity attributable to radiation
             resolved to ≤grade 1

          8. ≥ 8 weeks since the last dose of strontium or samarium

          9. Sexually active patients must agree to use adequate contraception

         10. Karnofsky Performance Status ≥ 60%

         11. Life expectancy &gt;12 weeks

         12. Required initial laboratory values Absolute neutrophil count &gt; 1500/ul Platelets &gt;
             100,000/ul Hemoglobin &gt; 8.0 g/dl Creatinine ≤ 2.0 X upper limit of normal Bilirubin
             ≤upper limit of normal (ULN)

        aspartate aminotransferase (AST) / alanine aminotransferase (ALT) / alkaline phosphatase:
        AST AND ALT AND alkaline phosphatase must be within the range allowing for eligibility In
        determining eligibility, the more abnormal of the 2 values (AST or ALT should be used. An
        abnormal alkaline phosphatase must be attributed to liver dysfunction and not metastatic
        bone involvement (i.e elevated gamma-glutamyl transpeptidase (GGTP) or evidence of liver
        metastases)

        Inclusion criteria for late enrolling patients:

          1. Age over 18 years

          2. Histologically documented adenocarcinoma of the prostate

          3. ≤3 cycles of prior docetaxel chemotherapy for metastatic disease permitted prior to
             enrollment

          4. Docetaxel must have been administered on an every 3 week schedule

          5. Each docetaxel dose must have been between 60 and 75 mg/m2

          6. Castrate levels of testosterone &lt;50 ng/mL

          7. Daily use of other steroids (hydrocortisone, dexamethasone) instead of prednisone or
             no steroids, is permitted up until time of enrollment

          8. A Prostate-specific antigen (PSA) level must have been documented within 6 weeks of
             initiating docetaxel chemotherapy

        Exclusion Criteria:

          1. Prior systemic chemotherapy for prostate cancer, other than q 3-week
             docetaxel/prednisone. Prior neoadjuvant or adjuvant chemotherapy is permitted if there
             was no evidence of disease relapse within 12 months of the last dose of chemotherapy.

          2. &gt;3 cycles of q3 week docetaxel/prednisone chemotherapy has already been administered
             to the patient

          3. Peripheral neuropathy &gt;grade 1

          4. Prior immunotherapy including systemic GM-CSF or vaccines utilizing GM-CSF; prior
             G-CSF support of chemotherapy-related neutropenia is permitted

          5. Prior biologic agents (i.e.,anti-angiogenic agents, anti-Epithelial Growth Factor
             Receptor (EGFR) inhibitors)≤ 4 weeks prior to registration

          6. More than two prior therapies with an investigational agent, completed ≤ 4 weeks prior
             to enrollment (no prior immunotherapeutics are allowed)

          7. Myocardial infarction or significant change in anginal pattern within the last 6
             months, symptomatic congestive heart failure (NYHA Class III or higher) or
             uncontrolled cardiac arrhythmia

          8. Because patients with immune deficiency are at increased risk of lethal infections
             when treated with marrow-suppressive therapy, HIV-positive patients receiving
             combination anti-retroviral therapy are excluded

          9. Patients with a history of severe hypersensitivity reaction to docetaxel or other
             drugs formulated with polysorbate 80 will be excluded

         10. Poorly controlled diabetes (fasting blood glucose &gt;250) despite optimization of
             medical therapy

        Exclusion criteria for late enrolling patients:

          1. Prior immunotherapy including systemic GM-CSF or vaccines utilizing GM-CSF; prior
             G-CSF support for chemotherapy-related neutropenia is permitted

          2. Delay of ≥6 weeks between any 2 chemotherapy cycles prior to enrollment on study

          3. Cumulative delays ≥8 weeks between chemotherapy cycles prior to enrollment on study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <results_first_submitted>October 7, 2019</results_first_submitted>
  <results_first_submitted_qc>October 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2019</results_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Hormone Refractory Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients had to complete 6 cycles of induction chemotherapy and have a ≥ 50% decline in prostate-specific antigen to be eligible for randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-Randomization</title>
          <description>Induction chemotherapy for 6 cycles (1 cycle = 21 days)
Docetaxel 75mg/m^2 I.V. (intravenous) on day 2
Prednisone 5 mg by mouth (p.o.), twice a day (b.i.d.) from day 1 to 21 (for 21 days)</description>
        </group>
        <group group_id="P2">
          <title>Docetaxel and Observation</title>
          <description>Docetaxel 75mg/m^2 every 21 days</description>
        </group>
        <group group_id="P3">
          <title>Docetaxel and GM-CSF</title>
          <description>Docetaxel 75mg/m^2 every 21 days and GM-CSF 250mcg/m^2 subcutaneously days 15-28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Chemotherapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Cycles Completed</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>≥ 50% Prostate-specific Antigen Decline</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Course 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>nonprotocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Course 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Course 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Response to Course 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Induction Chemotherapy: Total number of patients enrolled, starting trial.
Docetaxel/Docetaxel and GM-CSF: patients which passed 6 cycles of induction chemotherapy and had a ≥ 50 % PSA decline</population>
      <group_list>
        <group group_id="B1">
          <title>All Patients Accrued</title>
          <description>There were a total of 125 patients whom were accrued to the study and assigned to at least one course of docetaxel</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Median Age Range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="47" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>The Gleason Score ranges from 1-8. Scores of 1-5 describe how much the cancer from a biopsy looks like healthy tissue (lower score) or abnormal tissue (higher score). Typical Gleason Scores range from 6-10. The higher the Gleason Score, the more likely that the cancer will grow and spread quickly. Since prostate tumors are often made up of cancerous cells with different grades, two grades are assigned for each patient. A primary grade for cells that make up the largest area of tumor and a secondary grade for cells of next largest area. Together they make up the total Gleason Score.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression</title>
        <description>The Kaplan-Meier product limit method with 95% confidence intervals will be used to estimate the median time to disease progression during initial course of randomized treatment</description>
        <time_frame>Up to 7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Observation</title>
            <description>- Docetaxel 75mg/m^2 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel and GM-CSF</title>
            <description>Docetaxel 75mg/m^2 every 21 days
GM-CSF 250mcg/m2 subcutaneous (SQ) days 15-28</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>The Kaplan-Meier product limit method with 95% confidence intervals will be used to estimate the median time to disease progression during initial course of randomized treatment</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.5" upper_limit="2.4"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.4" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The Kaplan-Meier product limit method will be used to estimate the median overall survival</description>
        <time_frame>Up to 7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Observation</title>
            <description>Docetaxel 75mg/m2 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel and GM-CSF</title>
            <description>Docetaxel 75mg/m2 every 21 days GM-CSF 250mcg/m2 SQ days 15-28</description>
          </group>
          <group group_id="O3">
            <title>Overall Survival</title>
            <description>Includes all patients whom received any treatment starting with first course of Docetaxel at Induction</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The Kaplan-Meier product limit method will be used to estimate the median overall survival</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10.5" upper_limit="27.6"/>
                    <measurement group_id="O2" value="28.4" lower_limit="19.2" upper_limit="34.1"/>
                    <measurement group_id="O3" value="15.6" lower_limit="13.1" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With PSA Response to Successive Series of Chemotherapy</title>
        <description>PSA partial response is defined by at least a 50% decline from PSA value from the baseline measurement to 12 weeks of protocol therapy. The decline must be confirmed by a second PSA value obtained 4 or more weeks later For those patients whose PSA have decreased but has not reached response criteria defined above, progressive disease is defined as 25% increase over the nadir PSA value provided that the increase is at least 5ng/mL and is confirmed.</description>
        <time_frame>Up to 6 years</time_frame>
        <population>Twenty-six participants total resumed a second course of the Docetaxel, and five participants went on to resume a third course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Observation</title>
            <description>- Docetaxel 75mg/m2 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel and GM-CSF</title>
            <description>Docetaxel 75mg/m2 every 21 days
GM-CSF 250mcg/m2 SQ days 15-28</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PSA Response to Successive Series of Chemotherapy</title>
          <description>PSA partial response is defined by at least a 50% decline from PSA value from the baseline measurement to 12 weeks of protocol therapy. The decline must be confirmed by a second PSA value obtained 4 or more weeks later For those patients whose PSA have decreased but has not reached response criteria defined above, progressive disease is defined as 25% increase over the nadir PSA value provided that the increase is at least 5ng/mL and is confirmed.</description>
          <population>Twenty-six participants total resumed a second course of the Docetaxel, and five participants went on to resume a third course of treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA response to Course 2 chemotherapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA response to Course 3 chemotherapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Duration of Time on and Off Docetaxel-based Therapy</title>
        <description>Median percentage of time will be calculated to summarize the total duration of chemotherapy and amount of docetaxel/prednisone administered while the patient is on study. The same results will be tabulated for each. For the on-chemotherapy period: will be estimated from the date of starting protocol therapy; if a patient received docetaxel on day 2 of a cycle, he will be considered to have received a full 21 days on therapy. For the off-chemotherapy period: will be calculated from the date of starting the observation or GM-CSF period to the date of resuming chemotherapy</description>
        <time_frame>Up to 7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Observation OFF Chemotherapy</title>
            <description>Starting the docetaxel with observation period to date of resuming chemotherapy post initial induction</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel and GM-CSF OFF Chemotherapy</title>
            <description>Starting the docetaxel with GM-CSF period to date of resuming chemotherapy post initial induction</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel + Observation ON Chemotherapy</title>
            <description>Starting Docetaxel 75mg/m2 and Observation every 21 days for at least 2 days</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel and GM-CSF ON Chemotherapy</title>
            <description>Starting Docetaxel 75mg/m2 and GM-CSF 250mcg/m2 SQ days 15-28 every 28 days with at least 2 days of Docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Duration of Time on and Off Docetaxel-based Therapy</title>
          <description>Median percentage of time will be calculated to summarize the total duration of chemotherapy and amount of docetaxel/prednisone administered while the patient is on study. The same results will be tabulated for each. For the on-chemotherapy period: will be estimated from the date of starting protocol therapy; if a patient received docetaxel on day 2 of a cycle, he will be considered to have received a full 21 days on therapy. For the off-chemotherapy period: will be calculated from the date of starting the observation or GM-CSF period to the date of resuming chemotherapy</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="0.8" upper_limit="50.8"/>
                    <measurement group_id="O2" value="30.9" lower_limit="1.7" upper_limit="77.1"/>
                    <measurement group_id="O3" value="8.3" lower_limit="3.9" upper_limit="22.8"/>
                    <measurement group_id="O4" value="7.6" lower_limit="1.9" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Any patient receiving at least one dose of the study treatment will be included in the analyses of toxicity during the initial chemotherapy period, but patients who cancel registration before receiving any therapy will not. All grade 3-5, expected and unexpected adverse events (AEs) were collected at all study visits from time of first treatment until at least 28 days following the last dose of study drug.</time_frame>
      <desc>Data was not collected per intervention. All patients were assigned to the same treatment of Docetaxel/Prednisone before being assigned to the subsequent therapy arms where they may have received multiple treatment courses with multiple inductions. Abnormal lab values or test results constituted AEs only if they induced clinical signs /symptoms, required therapy, or required dose modification. There were no treatment-associated deaths.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Accrued Patients</title>
          <description>All patients were assigned to received six 21-day cycles of docetaxel 75 mg/m2 on Day 2 of each cycle and 5 mg prednisone twice a day on Days 1-21. Following six cycles of chemotherapy, eligible subjects were randomized to no maintenance therapy or to maintenance GM-CSF therapy. Patients in both groups were followed until disease progression at which time GM-CSF was discontinued and another course of docetaxel and prednisone was administered again.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rahul Aggarwal</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 353-9278</phone>
      <email>Rahul.Aggarwal@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

